DigestRedComo funciona
Red
/
Empresas
Ta
No verificado

Takeda Pharmaceutical Company Limited

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

51 Comunicados de prensa

Ver todos los comunicados de prensa
15/06/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
11/06/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Higiene alimentaria
Medicina - Varios
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
09/06/2026
Industria
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
13/05/2026
Web y redes sociales
Telefonía
Mercado de valores
Acciones y Obligaciones
Biotecnología
Farmacéutica
Salud
Oncología
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
04/05/2026
Industria
Salud
Ciencia
Farmacéutica
Medicina - Varios
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
28/03/2026
Eventos
Industria
Web y redes sociales
Telefonía
Salud
Medicina - Varios
Sanidad
Ciencia
Farmacéutica
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
02/03/2026
Industria
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
19/02/2026
Industria
Salud
Ciencia
Farmacéutica
Medicina - Varios
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
10/02/2026
Industria
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
29/01/2026
Biotecnología
Farmacéutica
Salud
Oncología
Mercado de valores
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0